Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15–23-year-old women attending a youth health clinic in Stockholm, Sweden

References

• Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–27.
   PubMed Web of Science ®Google Scholar
• Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001;37: 246–50.
   PubMed Web of Science ®Google Scholar
• Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–8.
   PubMed Web of Science ®Google Scholar
• Ivansson EL, Gustavsson IM, Wilander E, Magnusson PK, Gyllensten UB. Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. Int J Cancer 2009;125:2930–5.
   PubMedGoogle Scholar
• Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 2006;24(Suppl 1):S1–15.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–8.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, . Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757–65.
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247–55.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, . High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459–66.
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009;199:926–35.
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301–14.
   PubMed Web of Science ®Google Scholar
• de Sanjosé S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, . Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453–9.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504–12.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008;46:1050–9.
   PubMedGoogle Scholar
• Auvinen E, Niemi M, Malm C, Zilliacus R, Trontti A, Fingerroos R, . High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005;37:873–6.
   PubMed Web of Science ®Google Scholar
• Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008;98:646–51.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123:1864–70.
   PubMed Web of Science ®Google Scholar
• Leinonen M, Kotaniemi-Talonen L, Anttila A, Dyba T, Tarkkanen J, Nieminen P. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008;123:1344–9.
   PubMed Web of Science ®Google Scholar
• Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, . Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008;3:e3743.
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, . Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10): K1–16.
   PubMed Web of Science ®Google Scholar
• Uuskula A, Kals M, Kosenkranius L, McNutt LA, DeHovitz JJ. Population-based type-specific prevalence of high-risk human papillomavirus infection in Estonia. BMC Infect Dis 2010;10:63.
   PubMedGoogle Scholar
• Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.
   PubMedGoogle Scholar
• Keita N, Clifford GM, Koulibaly M, Douno K, Kabba I, Haba M, . HPV infection in women with and without cervical cancer in Conakry, Guinea. Br J Cancer 2009; 101:202–8.
   PubMedGoogle Scholar
• Ammatuna P, Giovannelli L, Matranga D, Ciriminna S, Perino A. Prevalence of genital human papilloma virus infection and genotypes among young women in Sicily, South Italy. Cancer Epidemiol Biomarkers Prev 2008;17:2002–6.
   PubMed Web of Science ®Google Scholar
• Sturegard E, Johnsson A, Gustafsson E, Dillner J. [Condyloma typing important for follow up of HPV vaccination. A condyloma reporting project]. Lakartidningen 2008;105: 3648–50.
   PubMedGoogle Scholar
• Dahlgren L, Mellin H, Wangsa D, Heselmeyer-Haddad K, Bjornestal L, Lindholm J, . Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003;107: 244–9.
   PubMedGoogle Scholar
• Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer 2005;92:891–4.
   PubMed Web of Science ®Google Scholar
• Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3): S3/26–34.
   Google Scholar
• Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, . Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743–53.
   PubMed Web of Science ®Google Scholar